# Fasciotens

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fasciotens

- Industry: Medical Devices & Equipment
- Headquarters: Essen, Germany
- Website: www.fasciotens.de
- Total disclosed funding: $3.1M
- Latest round: Series A (Jun 8, 2018)
- Investors on record: 2

## About

Fasciotens GmbH is a medical device company that specializes in innovative solutions for abdominal wall reconstruction, targeting complex challenges related to hernias and congenital defects.Founded in 2016 and headquartered in Essen, Germany, Fasciotens GmbH focuses on developing advanced products for abdominal wall management. The company raised EUR 2.6 million in Series A funding in June 2018 from investors Coparion and aws Fondsmanagement, bringing the total amount raised to EUR 2.6 million. The company has completed one major deal since its inception.Fasciotens specializes in innovative solutions for abdominal wall reconstruction, focusing on a suite of products designed to address complex medical challenges associated with hernias and congenital defects. Their core offerings include fasciotens® for abdominal wall management, which increases intra-abdominal volume during open abdomen therapy, and fasciotens®HERNIA, which facilitates the stretching of the abdominal wall in complex hernia treatments to restore anatomical integrity. Additionally, fasciotens®PEDIATRIC is tailored for newborns, specifically addressing congenital defects like gastroschisis and omphaloceles. These products are primarily utilized by healthcare professionals, including surgeons and medical staff, in hospitals and specialized medical centers across various geographical markets, with a notable presence in Europe and North America.Fasciotens generates revenue through direct sales of its medical devices to healthcare institutions, including hospitals and surgical centers. Transactions are structured on a B2B basis, where medical facilities procure fasciotens products for use in surgical procedures. The pricing model for these specialized medical solutions is typically based on individual product sales, with emphasis on flagship offerings such as fasciotens®HERNIA and fasciotens®Abdomen, which are integral to advancing surgical practices in hernia repair and abdominal cavity management. The company maintains partnerships with local distribution partners to enhance market reach and facilitate the delivery of its products to healthcare providers, ensuring that surgical teams have access to essential technologies for improving patient outcomes.Fasciotens GmbH aims to leverage the EUR 2.6 million raised in its most recent funding round to enhance its product development and market expansion strategies. The company is in the process of designing new products specifically targeted at addressing additional complex medical conditions and plans to introduce these innovations by 2023. Furthermore, Fasciotens is looking to expand into new geographic markets within Asia and South America, aiming for entry by the end of 2024, thereby broadening its global footprint.

## Funding rounds

- Series A, Jun 8, 2018, $3.1M — aws Fondsmanagement, Coparion

## Investors

- aws Fondsmanagement (https://capitalatlas.ai/funds/aws-fondsmanagement) — Series A
- Coparion (https://capitalatlas.ai/funds/coparion) — Series A